Baird raised the firm’s price target on Alto Neuroscience (ANRO) to $16 from $10 and keeps an Outperform rating on the shares. The firm updated its model following the recent financing which shuld accelerate the timeline for the development of ALTO-207.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience Secures $50M in Private Placement
- Alto Neuroscience, Inc.: Accelerated Drug Development and Strong Clinical Trial Compliance Drive Buy Rating
- Midday Fly By: AWS hit by outage, Kering sells beauty unit
- Alto Neuroscience, Inc.: Strategic Advancements and Financial Strength Drive Buy Rating
- Alto Neuroscience price target raised to $16 from $10 at Baird